Australian biotech sues GlaxoSmithKline for $325M

Biota Holdings is suing GlaxoSmithKline over the drug giant's alleged failure to support the smaller company's flu drug, Relenza. GlaxoSmithKline holds the license to develop and commercialize the drug, which Biota claims would have captured 40 percent market share with proper support. Relenza currently has about 5 percent of the flu market. That alleged lack of market support cost Biota up to $325 million, the company claims.

- read this story from Asia Pulse for more

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.